



# 2013 AMDM Annual Meeting Agenda

Wednesday

April 17, 2013

11:00 a.m. – 5:45 p.m.

---

<b>11:00 – 11:15 a.m.</b>	<b>Welcome</b> Judi Smith, AMDM President Karin Hughes, AMDM Annual Meeting Co-Chair Donna Link, AMDM Annual Meeting Co-Chair	Room: White Flint Amphitheatre
<b>11:15 – 12:15</b>	<b>Roundtable Discussion with OIR Management Team</b> Alberto Gutierrez, Ph.D., Director, Office of In Vitro Diagnostics and Radiological Health <i>alberto.gutierrez@fda.hhs.gov</i>	
<b>12:15 – 1:15</b>	<b>Lunch</b>	White Oak
<b>1:15 – 2:00</b>	<b>IVD Industry Overview</b> Jonathan Kahan, Partner, Hogan Lovells <i>Jonathan.kahan@hoganlovells.com</i>	
<b>2:00 – 2:30</b>	<b>Pre-De Novo /De Novo Submission Process</b> Scott McFarland, Policy Advisor, CDRH, FDA <i>scott.mcfarland@fda.hhs.gov</i>	
<b>2:30 – 2:45</b>	<b>Break</b>	
<b>2:45 – 3:15</b>	<b>Ten Tips for IVD Manufacturers</b> Jeffrey N. Gibbs, Director, Hyman, Phelps & McNamara <i>jgibbs@hpm.com</i>	
<b>3:15 – 3:45</b>	<b>Mobile Medical Applications Guidance</b> Brendan O’Leary, Public Health Analyst, CDRH, OIR <i>brendan.oleary@fda.hhs.gov</i>	
<b>3:45 – 4:00</b>	<b>Break</b>	
<b>4:00 – 4:45</b>	<b>EP-17A CLSI Guideline on Determination Limits of Detection &amp; Quantitation</b> (Focus on LoQ and total error specification) <b>Marina V. Kondratovich, Ph.D., Associate Director for Clinical Studies, Personalized Medicine, OIR, CDRH, FDA</b> <i>marina.kondratovich@fda.hhs.gov</i>	
<b>4:45 – 5:15</b>	<b>How to Successfully Migrate Assays following the 2009 FDA Draft Guidance Policy</b> Christopher Bentsen, Manager, Regulatory Affairs, Quality Assurance and Clinical Affairs, Bio-Rad Laboratories <i>Christopher_bentsen@bio-rad.com</i>	
<b>5:15 – 5:45</b>	<b>AMDM Annual Business Meeting</b>	

---



# 2013 AMDM Annual Meeting Agenda

Thursday

April 18, 2013

9:00 a.m. – 3:00 p.m.

---

8:00 – 9:00 a.m.	<b>Complimentary Breakfast Buffet</b>	White Flint Amphitheatre
9:00 – 9:45	<b>The Changing Regulatory Environment-What to Expect in 2013 and Beyond</b> Rick Naples, Sr. VP, Regulatory Affairs, Becton-Dickinson <i>Christine_pasquariello@bd.com</i>	
9:45 – 10:30	<b>Personalized Medicine</b> Elizabeth Mansfield, Ph.D., Director, Personalized Medicine, OIR, CDRH, FDA <i>elizabeth.mansfield@fda.hhs.gov</i>	
10:30 – 10:45	<b>Break</b>	
10:45 – 11:30	<b>The Future of LDT's and their Impact on the IVD Industry</b> Bradley Merrill Thompson, Member of the Firm, Epstein Becker Green <i>BThompson@EBGLAW.com</i>	
11:30 – 12:00	<b>Compliance Update: What's Old is New Again</b> Sheri Hall, Vice President, Quality & Regulatory Affairs, BD Bioscience <i>Sheri.hall@bd.com</i>	
12:00 – 1:00	<b>Lunch</b>	White Oak
1:00 – 1:30	<b>Changes to the IVD Regulations in Europe: What, When, Hot Topics and Areas of Uncertainty</b> Sue Spencer, Head of IVD BSI Group, United Kingdom <i>Sue.spencer@bsigroup.com</i>	
1:30 – 2:00	<b>Trends in IVD Deficiencies-A Compliance Perspective</b> Joshua Levin, Lead Consumer Safety Officer, SVGR, FDA <i>Joshua.levin@fda.hhs.gov</i>	
2:00 - 2:15	<b>Review &amp; Wrap Up</b> Judi Smith, AMDM President Karin Hughes, AMDM Annual Meeting Co-Chair Donna Link, AMDM Annual Meeting Co-Chair	

---